# US 2020/0267992 A1 · Altering microbial populations & modifying microbiota

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0267992 A1
- Document ID: US20200267992A1
- Status: Published application
- Kind: A1
- Application number: 16/858,333
- Filed: 2020-04-24
- Published: 2020-08-27
- Earliest claimed: 2015-05-06
- Assignees: SNIPR Technologies Limited
- Applicants: SNIPR Technologies Limited
- Inventors: Jasper CLUBE
- Web page: https://patentgrep.com/patent/US20200267992A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A01N 63/00: Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates (containing compounds of determined constitution A01N27/00 - A01N59/00; unicellular algae A01N65/03)
- A01N 63/50: Isolated enzymes; Isolated proteins (peptides A01N37/46)
- A01N 63/60: Isolated nucleic acids
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 1/20: Bacteria; Culture media therefor
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/746: {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- C12N 15/902: {using homologous recombination}
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/31: Combination therapy
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/10132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

## Claims

### Claim at position 1

1: An engineered virus that is capable of transforming a host cell, the engineered virus
(a) comprising a nucleic acid sequence encoding a crRNA; and
(b) lacking a nucleic acid sequence encoding a Cas nuclease that is operable with the crRNA;
wherein the crRNA is operable with a Cas nuclease in a host cell to guide Cas nuclease modification of a target sequence in the host cell; and wherein the nucleic acid sequence encoding the crRNA does not comprise a protospacer adjacent motif (PAM) recognized by the Cas nuclease.

### Claim at position 2 (depends on 1)

2: The virus of claim 1, wherein the crRNA is comprised by a single guide RNA.

### Claim at position 3 (depends on 1)

3: The virus of claim 1, wherein the Cas nuclease is a dead Cas (dCas).

### Claim at position 4 (depends on 1)

4: The virus of claim 1, wherein the nucleic acid sequence encoding the crRNA comprises a constitutive promoter.

### Claim 5

(canceled)

### Claim at position 6 (depends on 1)

6: The virus of claim 1, wherein the virus is a phage.

### Claim at position 7 (depends on 6)

7: The virus of claim 6, wherein the phage is capable of infecting an E coli, Streptocccus, Staphylococcus, Pseudomonas, Vibrio, Neisseria, Bordetella, Haemophilus, Shigella, Brucella, Francisellam Xanthomonas, Agrobacterium, Erwinia, Legionella, Listeria, Campylobacter, Yersinia, Borelia, Helicobacter, Clostridium, Salmonella, Chlamydia, Parachlamydia, Corynebacterium, Klebsiella, Enterococcus or Acinetobacter cell.

### Claim at position 8 (depends on 1)

8: The virus of claim 1, wherein the virus is a virophage.

### Claim at position 9 (depends on 1)

9: The virus of claim 1, wherein the host cell is a bacterial or archaeal host cell.

### Claim 10

(canceled)

### Claim at position 11 (depends on 1)

11: The virus of claim 1, wherein the virus is a Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae or Tectivirdae virus.

### Claim 12

(canceled)

### Claim at position 13 (depends on 1)

13: The virus of claim 1, wherein the nucleic acid sequence encoding crRNA comprises a host-modifying array (HM-array) for producing the crRNA, wherein the Cas nuclease is a Cas nuclease of a CRISPR/Cas system, wherein the system comprises a CRISPR array comprising a repeat sequence, wherein the HM-array comprises a CRISPR repeat sequence that is at least about 95% identical to repeat sequence of said system.

### Claim 14

(canceled)

### Claim at position 15 (depends on 1)

15: The virus of claim 1, wherein the nucleic acid sequence encoding the crRNA comprises an HM-array, wherein the HM-array comprises a spacer sequence (HM-spacer) and repeat sequences, wherein the first HM-spacer and repeat sequences encode the crRNA.

### Claim at position 16 (depends on 15)

16: The virus of claim 15, wherein the virus comprises a second nucleic acid sequence that encodes a second crRNA, wherein the second crRNA is operable with a second Cas in the host cell, and wherein the second crRNA comprises a nucleic acid sequence that is capable of hybridizing to a second host target sequence to guide Cas modification of the second target sequence in the host cell.

### Claim at position 17 (depends on 1)

17: The virus of claim 1, wherein the virus comprises a nucleic acid sequence encoding an exogenous Cas that is functional in the host cell.

### Claim at position 18 (depends on 16)

18: The virus of claim 16, wherein the virus comprises a nucleic acid sequence encoding an exogenous Cas that is functional in the host cell, wherein the second crRNA is operable with the exogenous Cas in the host cell to guide Cas modification of the second target sequence in the host cell.

### Claim at position 19 (depends on 17)

19: The virus of claim 17, wherein
(i) the exogenous Cas is a Type I Cas and the host cell has an endogenous Type II or III Cas;
(ii) the exogenous Cas is a Type II Cas and the host cell has an endogenous Type I or III Cas;
(iii) the exogenous Cas is a Type III Cas and the host cell has an endogenous Type I or II Cas; or
(iv) the host cell does not express a Type of Cas that is the same as the Type of the exogenous Cas.

### Claim at position 20 (depends on 18)

20: The virus of claim 18, wherein
(i) the exogenous Cas is a Type I Cas and the host cell has an endogenous Type II or III Cas;
(ii) the exogenous Cas is a Type II Cas and the host cell has an endogenous Type I or III Cas;
(iii) the exogenous Cas is a Type III Cas and the host cell has an endogenous Type I or II Cas; or
(iv) the host cell does not express a Type of Cas that is the same as the Type of the exogenous Cas.

### Claim at position 21 (depends on 1)

21: The virus of claim 1 wherein the nucleic acid sequence encoding the crRNA does not comprise a PAM recognized by Cas9.

### Claim at position 22 (depends on 16)

22: The virus of claim 16, wherein the nucleic acid sequence encoding the crRNA comprises a first HM-array of a first CRISPR/Cas Type and the second nucleic acid sequence encoding the second crRNA comprises a second HM-array of a second CRISPR/Cas Type.

### Claim at position 23 (depends on 22)

23: The virus of claim 22, wherein
(a) the first HM-array is a Type II array and the second HM-array is a Type I or III array;
(b) the first HM-array is a Type II-A array and the second HM-array is a Type II-B array;
(c) the second HM-array is a Type II array and the first HM-array is a Type I or III array; or
(d) the second HM-array is a Type II-A array and the first HM-array is a Type II-B array.

### Claim at position 24 (depends on 16)

24: The virus of claim 16, wherein the first crRNA is operable with an endogenous Cas nuclease of the host cell and the second crRNA is operable with an exogenous Cas nuclease.

### Claim at position 25 (depends on 16)

25: The virus of claim 16, wherein the virus comprises a Cas nuclease sequence that is not encoded by the host cell and that is cognate to repeat sequences of the second crRNA.

### Claim 26 (depends on 1)

The engineered virus of claim 1, wherein the engineered virus
lacks a nucleic acid sequence encoding a Type II Cas nuclease;
wherein the crRNA is operable with a Type I Cas nuclease in a host cell to guide Cas nuclease modification of a target sequence in the host cell, and wherein the nucleic acid sequence does not comprise a PAM recognized by the Type I Cas nuclease.

### Claim 27 (depends on 1)

The engineered virus of claim 1, wherein the engineered virus
lacks a nucleic acid sequence encoding a Type II Cas nuclease;
wherein the crRNA is operable with a Type II Cas nuclease in a host cell to guide Cas nuclease modification of a target sequence in the host cell, and wherein the nucleic acid sequence does not comprise a PAM recognized by the Type II Cas nuclease.

### Claim 28 (depends on 1)

The engineered virus of claim 1, wherein the engineered virus
lacks a nucleic acid sequence encoding a Type III Cas nuclease;
wherein the crRNA is operable with a Type III Cas nuclease in a host cell to guide Cas nuclease modification of a target sequence in the host cell, and wherein the nucleic acid sequence does not comprise a PAM recognized by the Type III Cas nuclease.

### Claim at position 29 (depends on 26)

29: The engineered virus of claim 26, wherein the host cell comprises an endogenous Type I Cas nuclease and the nucleic acid sequence does not comprise a PAM recognized by the endogenous Type I Cas nuclease.

### Claim at position 30 (depends on 27)

30: The engineered virus of claim 27, wherein the host cell comprises an endogenous Type II Cas nuclease and the nucleic acid sequence does not comprise a PAM recognized by the endogenous Type II Cas nuclease.

### Claim at position 31 (depends on 28)

31: The engineered virus of claim 28, wherein the host cell comprises an endogenous Type III Cas nuclease and the nucleic acid sequence does not comprise a PAM recognized by the endogenous Type III Cas nuclease.

### Claim at position 32

32: An engineered virus that is capable of transforming a host cell, the engineered virus comprising:
(a) a first nucleic acid sequence encoding a first crRNA, wherein the first crRNA is operable with a first Cas nuclease in a host cell to guide Cas nuclease modification of a first target sequence in the host cell, and wherein first the nucleic acid sequence does not comprise a PAM recognized by the first Cas nuclease; and
(b) a second nucleic acid sequence that encodes a second crRNA, wherein the second crRNA is operable with a second Cas nuclease in the host cell to guide Cas modification of a second target sequence in the host cell, and wherein second the nucleic acid sequence does not comprise a PAM recognized by the second Cas nuclease.

### Claim at position 33 (depends on 32)

33: The engineered virus of claim 32, wherein the first Cas nuclease and the second Cas nuclease are the same.

### Claim at position 34 (depends on 32)

34: The engineered virus of claim 32, wherein the first Cas nuclease and the second Cas nuclease are different.
